Price Alert

Selecta Biosciences Inc. (SELB)

NASDAQ: SELB · Real-Time Price · USD

0.88

-0.08 (-8.12%)

At close: Nov 13, 2023, 10:00 PM

Selecta Biosciences Statistics

Share Statistics

Selecta Biosciences has 153.43M shares outstanding. The number of shares has increased by 0% in one year.

Shares Outstanding	153.43M
Shares Change (YoY)	0%
Shares Change (QoQ)	0%
Owned by Institutions (%)	n/a
Shares Floating	94M
Failed to Deliver (FTD) Shares	8
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 7.98M, so 5.2% of the outstanding shares have been sold short.

Short Interest	7.98M
Short % of Shares Out	5.2%
Short % of Float	7.8%
Short Ratio (days to cover)	17.33

Valuation Ratios

The PE ratio is -1.34 and the forward PE ratio is null. Selecta Biosciences's PEG ratio is 0.02.

PE Ratio	-1.34
Forward PE	n/a
PS Ratio	2.66
Forward PS	n/a
PB Ratio	-15.22
P/FCF Ratio	-3.16
PEG Ratio	0.02

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Selecta Biosciences.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 9.43, with a Debt / Equity ratio of -2.06.

Current Ratio	9.43
Quick Ratio	9.43
Debt / Equity	-2.06
Debt / EBITDA	n/a
Debt / FCF	-0.43
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$608.02K
Profits Per Employee	$-1.21M
Employee Count	64
Asset Turnover	0.09
Inventory Turnover	n/a

Taxes

Income Tax	-287K
Effective Tax Rate	0.37%

Stock Price Statistics

The stock price has increased by 31.87% in the last 52 weeks. The beta is 0.83, so Selecta Biosciences's price volatility has been higher than the market average.

Beta	0.83
52-Week Price Change	31.87%
50-Day Moving Average	1.07
200-Day Moving Average	1.17
Relative Strength Index (RSI)	37.34
Average Volume (20 Days)	634,418

Income Statement

In the last 12 months, Selecta Biosciences had revenue of 38.91M and earned -77.42M in profits. Earnings per share was -0.5.

Revenue	38.91M
Gross Profit	n/a
Operating Income	n/a
Net Income	-77.42M
EBITDA	n/a
EBIT	n/a
Earnings Per Share (EPS)	-0.5

Full Income Statement

Balance Sheet

The company has 212.61M in cash and 13.98M in debt, giving a net cash position of 198.63M.

Cash & Cash Equivalents	212.61M
Total Debt	13.98M
Net Cash	198.63M
Retained Earnings	-692.07M
Total Assets	409.13M
Working Capital	170.12M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -23.67M and capital expenditures -9.09M, giving a free cash flow of -32.77M.

Operating Cash Flow	-23.67M
Capital Expenditures	-9.09M
Free Cash Flow	-32.77M
FCF Per Share	-0.21

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	-198.23%
Profit Margin	-198.97%
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	-84.21%

Dividends & Yields

SELB does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for SELB.

Price Target	n/a
Price Target Difference	n/a
Analyst Consensus	n/a
Analyst Count	n/a

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	-2.09
Piotroski F-Score	3